a CD200R fusion protein for the treatment of atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis ...

Introduction: Ovarian cancer (OC) exhibits high mortality and chemoresistance rates, underscoring the urgent need for precise prognostic biomarkers and novel therapeutic targets. SUMOylation, crucial ...